ArticlePoultry science2026
Antimicrobial resistance of commensal and extended-spectrum ß-lactamase/AmpC-producing Escherichia coli in organic meat chicken farms.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We examined the antimicrobial resistance of commensal Escherichia coli and occurrence of extended-spectrum beta-lactamase (ESBL)-/AmpC-producing E. coli in organic meat chicken flocks of three different fattening types using a longitudinal study design. Fourteen German small scale meat chicken farms fattening either slow-growing broiler, dual-purpose cockerels or male layer hybrids were sampled between 2023 and 2025. Throughout the fattening period, four consecutive flocks per farm were sampled five times each. Three isolates per sampling time point were picked from MacConkey agar (MCA). Additionally, MCA + 1mg/L cefotaxime (MCA+CTX) was used to selectively screen for ESBL-/AmpC-producing E. coli. In total, 696 commensal E. coli from MCA and 51 ESBL-/AmpC-producing E. coli from MCA+CTX were isolated. Antimicrobial resistance was determined using broth microdilution and minimum inhibitory concentrations were evaluated using epidemiological cut-off values. Throughout the fattening period, most commensal E. coli were susceptible in slow-growing broilers (63.0-80.0%), male layer hybrids (76.9-97.6%) and dual-purpose cockerels (69.0-89.6%). Resistance to ampicillin (11.1%; 77/696), ciprofloxacin (9.9%; 69/696), tetracycline (9.5%; 66/696), and nalidixic acid (8.3%; 58/696) was overall most prevalent in resistant commensal isolates regardless of sampling time point and fattening type. Whole genome sequencing revealed a diverse population among resistant commensal E. coli, with most resistant strains belonging to ST10 or ST155. Clonal dissemination of resistant strains was shown both within flocks or between subsequent flocks of a farm and between different farms. The providing hatchery was shown to have an influence (p < 0.001) on the recovery of resistant isolates. Only 27.5% of all flocks were positive for ESBL-/AmpC-producing E. coli for at least one sampling time point, with none of the flocks being positive throughout the whole fattening period and a high diversity of sequence types. bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.